Abstract

Background and aims: Radioiodine-refractory advanced or metastatic thyroid cancer has poor prognosis. We conducted a meta-analysis of randomized controlled trials to evaluate the effectiveness and safety of tyrosine kinase inhibitors (TKIs) for advanced or metastatic thyroid cancer treatment. Methods: Studies published up to April 2017 were selected. The pooled effect size was calculated through meta-analysis by using random effects models. Outcomes were overall survival (OS), progression-free survival (PFS), objective response rate (RR), and adverse events (AEs). Results: Six studies examining 1615 patients were included. TKI treatment significantly improved PFS in patients with differentiated thyroid cancer (DTC; hazard ratio [HR] = 0.43; 95% confidence interval [CI], 0.23–0.82) and those with medullary thyroid cancer (MTC; HR = 0.36; 95% CI, 0.22–0.58). TKI treatment significantly prolonged OS in patients with DTC (HR = 0.74; 95% CI, 0.58–0.95). The TKI treatment group exhibited a significantly improved partial response rate (risk ratio = 15.8; 95% CI, 1.77–140.69) but a significantly higher number of AEs compared with the control group. Conclusion: TKIs significantly improved PFS and RR in patients with advanced or metastatic DTC or MTC. We recommend thoroughly evaluating patients’ health status and cautiously using TKIs to maximize their benefits and minimize their toxicity.

Original languageEnglish
Pages (from-to)1-9
Number of pages9
JournalCurrent Medical Research and Opinion
DOIs
Publication statusPublished - 2018

Fingerprint

Thyroid Neoplasms
Protein-Tyrosine Kinases
Meta-Analysis
Randomized Controlled Trials
Confidence Intervals
Disease-Free Survival
Survival
Therapeutics
Health Status
Survival Rate
Odds Ratio
Safety
Control Groups

Keywords

  • meta-analysis
  • radioiodine refractory
  • targeted therapy
  • thyroid cancer
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Tyrosine kinase inhibitors for advanced or metastatic thyroid cancer : a meta-analysis of randomized controlled trials. / Liu, Jen Wei; Chen, Chiehfeng; Loh, El Wui; Chu, Chun Cheng; Wang, Mu Yi; Ouyang, Hsin Ju; Chang, Ya Ting; Zhuang, Wei Zhan; Chou, Ching Wen; Huang, Der Jr; Lee, Chia Hwa; Yen, Yun; Tam, Ka Wai.

In: Current Medical Research and Opinion, 2018, p. 1-9.

Research output: Contribution to journalArticle

Liu, Jen Wei ; Chen, Chiehfeng ; Loh, El Wui ; Chu, Chun Cheng ; Wang, Mu Yi ; Ouyang, Hsin Ju ; Chang, Ya Ting ; Zhuang, Wei Zhan ; Chou, Ching Wen ; Huang, Der Jr ; Lee, Chia Hwa ; Yen, Yun ; Tam, Ka Wai. / Tyrosine kinase inhibitors for advanced or metastatic thyroid cancer : a meta-analysis of randomized controlled trials. In: Current Medical Research and Opinion. 2018 ; pp. 1-9.
@article{9ed121a65f3348b8a58981fda261826f,
title = "Tyrosine kinase inhibitors for advanced or metastatic thyroid cancer: a meta-analysis of randomized controlled trials",
abstract = "Background and aims: Radioiodine-refractory advanced or metastatic thyroid cancer has poor prognosis. We conducted a meta-analysis of randomized controlled trials to evaluate the effectiveness and safety of tyrosine kinase inhibitors (TKIs) for advanced or metastatic thyroid cancer treatment. Methods: Studies published up to April 2017 were selected. The pooled effect size was calculated through meta-analysis by using random effects models. Outcomes were overall survival (OS), progression-free survival (PFS), objective response rate (RR), and adverse events (AEs). Results: Six studies examining 1615 patients were included. TKI treatment significantly improved PFS in patients with differentiated thyroid cancer (DTC; hazard ratio [HR] = 0.43; 95{\%} confidence interval [CI], 0.23–0.82) and those with medullary thyroid cancer (MTC; HR = 0.36; 95{\%} CI, 0.22–0.58). TKI treatment significantly prolonged OS in patients with DTC (HR = 0.74; 95{\%} CI, 0.58–0.95). The TKI treatment group exhibited a significantly improved partial response rate (risk ratio = 15.8; 95{\%} CI, 1.77–140.69) but a significantly higher number of AEs compared with the control group. Conclusion: TKIs significantly improved PFS and RR in patients with advanced or metastatic DTC or MTC. We recommend thoroughly evaluating patients’ health status and cautiously using TKIs to maximize their benefits and minimize their toxicity.",
keywords = "meta-analysis, radioiodine refractory, targeted therapy, thyroid cancer, Tyrosine kinase inhibitors",
author = "Liu, {Jen Wei} and Chiehfeng Chen and Loh, {El Wui} and Chu, {Chun Cheng} and Wang, {Mu Yi} and Ouyang, {Hsin Ju} and Chang, {Ya Ting} and Zhuang, {Wei Zhan} and Chou, {Ching Wen} and Huang, {Der Jr} and Lee, {Chia Hwa} and Yun Yen and Tam, {Ka Wai}",
year = "2018",
doi = "10.1080/03007995.2017.1368466",
language = "English",
pages = "1--9",
journal = "Current Medical Research and Opinion",
issn = "0300-7995",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Tyrosine kinase inhibitors for advanced or metastatic thyroid cancer

T2 - a meta-analysis of randomized controlled trials

AU - Liu, Jen Wei

AU - Chen, Chiehfeng

AU - Loh, El Wui

AU - Chu, Chun Cheng

AU - Wang, Mu Yi

AU - Ouyang, Hsin Ju

AU - Chang, Ya Ting

AU - Zhuang, Wei Zhan

AU - Chou, Ching Wen

AU - Huang, Der Jr

AU - Lee, Chia Hwa

AU - Yen, Yun

AU - Tam, Ka Wai

PY - 2018

Y1 - 2018

N2 - Background and aims: Radioiodine-refractory advanced or metastatic thyroid cancer has poor prognosis. We conducted a meta-analysis of randomized controlled trials to evaluate the effectiveness and safety of tyrosine kinase inhibitors (TKIs) for advanced or metastatic thyroid cancer treatment. Methods: Studies published up to April 2017 were selected. The pooled effect size was calculated through meta-analysis by using random effects models. Outcomes were overall survival (OS), progression-free survival (PFS), objective response rate (RR), and adverse events (AEs). Results: Six studies examining 1615 patients were included. TKI treatment significantly improved PFS in patients with differentiated thyroid cancer (DTC; hazard ratio [HR] = 0.43; 95% confidence interval [CI], 0.23–0.82) and those with medullary thyroid cancer (MTC; HR = 0.36; 95% CI, 0.22–0.58). TKI treatment significantly prolonged OS in patients with DTC (HR = 0.74; 95% CI, 0.58–0.95). The TKI treatment group exhibited a significantly improved partial response rate (risk ratio = 15.8; 95% CI, 1.77–140.69) but a significantly higher number of AEs compared with the control group. Conclusion: TKIs significantly improved PFS and RR in patients with advanced or metastatic DTC or MTC. We recommend thoroughly evaluating patients’ health status and cautiously using TKIs to maximize their benefits and minimize their toxicity.

AB - Background and aims: Radioiodine-refractory advanced or metastatic thyroid cancer has poor prognosis. We conducted a meta-analysis of randomized controlled trials to evaluate the effectiveness and safety of tyrosine kinase inhibitors (TKIs) for advanced or metastatic thyroid cancer treatment. Methods: Studies published up to April 2017 were selected. The pooled effect size was calculated through meta-analysis by using random effects models. Outcomes were overall survival (OS), progression-free survival (PFS), objective response rate (RR), and adverse events (AEs). Results: Six studies examining 1615 patients were included. TKI treatment significantly improved PFS in patients with differentiated thyroid cancer (DTC; hazard ratio [HR] = 0.43; 95% confidence interval [CI], 0.23–0.82) and those with medullary thyroid cancer (MTC; HR = 0.36; 95% CI, 0.22–0.58). TKI treatment significantly prolonged OS in patients with DTC (HR = 0.74; 95% CI, 0.58–0.95). The TKI treatment group exhibited a significantly improved partial response rate (risk ratio = 15.8; 95% CI, 1.77–140.69) but a significantly higher number of AEs compared with the control group. Conclusion: TKIs significantly improved PFS and RR in patients with advanced or metastatic DTC or MTC. We recommend thoroughly evaluating patients’ health status and cautiously using TKIs to maximize their benefits and minimize their toxicity.

KW - meta-analysis

KW - radioiodine refractory

KW - targeted therapy

KW - thyroid cancer

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85029435300&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029435300&partnerID=8YFLogxK

U2 - 10.1080/03007995.2017.1368466

DO - 10.1080/03007995.2017.1368466

M3 - Article

SP - 1

EP - 9

JO - Current Medical Research and Opinion

JF - Current Medical Research and Opinion

SN - 0300-7995

ER -